Question 1

What is Non-Small Cell Lung Cancer?

Accepted Answer

Non-Small Cell Lung Cancer (NSCLC) can be defined as epithelial lung cancer other than Small Cell Lung Cancer. NSCLC emerges from the epithelial cells of the lung of the central bronchi to terminal alveoli.

Question 2

At what CAGR, Non-Small Cell Lung Cancer market is growing in the 7 major markets (MM)?

Accepted Answer

Non-Small Cell Lung Cancer Market is expected to increase with a CAGR of 10.7% for the study period of 2017-2030.

Question 3

What was the total incident cases of Non-Small Cell Lung Cancer (NSCLC) in the 7MM in 2017?

Accepted Answer

The total NSCLC incident cases in the 7MM were 484,726 cases in 2017.

Question 4

What are the market drivers of Non-Small Cell Lung Cancer (NSCLC)?

Accepted Answer

Increasing use of biomarker testing, increasing incidence of the disease, increase in the mutation- specific trials activity and approval, and competitive landscape are the market drivers of Non-Small Cell Lung Cancer.

Question 5

What are the market barriers of Non-Small Cell Lung Cancer (NSCLC)?

Accepted Answer

Cost-effectiveness of therapies, small patient populations for specific subsets of NSCLC, cost of therapies, and generic or biosimilar erosion are the market barriers of Non-Small Cell Lung Cancer (NSCLC).

Question 6

Which are the emerging therapies in the Non-Small Cell Lung Cancer market?

Accepted Answer

Nazartinib (EGF816), Tepmetko (tepotinib), Merestinib, Vemurafenib Plus Cobimetinib, X-396 (Ensartinib), Plinabulin, Tedopi (OSE2101), SAR408701, TAK-788, and Veliparib (ABT-888) are the emerging therapies in the Non-Small Cell Lung Cancer market.

Question 7

Which are the leading companies in the Non-Small Cell Lung Cancer market?

Accepted Answer

Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie are the leading companies in the Non-Small Cell Lung Cancer market.